InterOcean Capital LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 7.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,098 shares of the biopharmaceutical company’s stock after selling 1,125 shares during the period. InterOcean Capital LLC’s holdings in Pfizer were worth $428,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the business. New England Investment & Retirement Group Inc. acquired a new position in shares of Pfizer during the first quarter worth $26,000. Lion Street Advisors LLC purchased a new stake in Pfizer during the 1st quarter worth about $27,000. Benjamin Edwards Inc. lifted its holdings in Pfizer by 49.8% during the 1st quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 335 shares during the last quarter. TFO TDC LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $37,000. Finally, Wealthcare Capital Management LLC increased its holdings in shares of Pfizer by 61.2% in the 4th quarter. Wealthcare Capital Management LLC now owns 1,069 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 406 shares during the last quarter. 69.91% of the stock is currently owned by institutional investors.
Shares of NYSE:PFE traded up $0.24 on Friday, reaching $37.50. The company’s stock had a trading volume of 14,885,114 shares, compared to its average volume of 22,354,300. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $44.56. The stock has a market capitalization of $206.97 billion, a P/E ratio of 12.85, a PEG ratio of 2.72 and a beta of 0.71. The stock’s 50-day moving average is $36.51 and its two-hundred day moving average is $36.84. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.02 and a quick ratio of 0.78.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.09. The firm had revenue of $12.03 billion for the quarter, compared to analysts’ expectations of $11.38 billion. Pfizer had a return on equity of 25.76% and a net margin of 31.17%. The firm’s revenue for the quarter was down 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.85 EPS. Equities analysts forecast that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 8th will be issued a $0.38 dividend. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.05%. The ex-dividend date of this dividend is Thursday, May 7th. Pfizer’s payout ratio is currently 51.53%.
In other news, EVP Douglas M. Lankler sold 65,000 shares of the business’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $37.85, for a total transaction of $2,460,250.00. Following the transaction, the executive vice president now directly owns 135,375 shares in the company, valued at $5,123,943.75. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Pfizer Inc purchased 312,500 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were purchased at an average cost of $16.00 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here. 0.08% of the stock is owned by corporate insiders.
A number of equities analysts recently issued reports on PFE shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $37.00 price target on shares of Pfizer in a report on Tuesday, January 28th. Mizuho restated a “buy” rating and issued a $42.00 target price on shares of Pfizer in a report on Monday, May 18th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $44.00 target price on shares of Pfizer in a research report on Monday, April 27th. Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 price target on shares of Pfizer in a research report on Thursday, March 19th. Finally, Standpoint Research raised Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, February 27th. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $41.28.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: Pattern Day Trader – What is the PDT Rule?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.